Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:exenatide
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A10BJ05
|
| gptkbp:brand |
gptkb:exenatide
|
| gptkbp:contraindication |
gptkb:medullary_thyroid_carcinoma
gptkb:multiple_endocrine_neoplasia_syndrome_type_2 |
| gptkbp:drugClass |
GLP-1 receptor agonist
|
| gptkbp:form |
extended-release suspension
|
| gptkbp:frequency |
once weekly
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bydureon
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
slows gastric emptying
increases insulin secretion suppresses glucagon secretion |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
nausea
diarrhea injection site reaction |
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|